PHGE · BiomX Inc

-

Please sign in to comment on PHGE

1 Comment

Admin

4 years, 1 month ago

BiomX Inc is currently in a long term downtrend where the price is trading 9.4% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

BiomX Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 57.0% to $-9M since the same quarter in the previous year.

Finally, its free cash flow grew by 61.7% to $-7M since the same quarter in the previous year.

Based on the above factors, BiomX Inc gets an overall score of 3/5.

CurrencyCode	USD
ISIN	US09090D1037
Exchange	NYSE MKT
Sector	Healthcare
Industry	Biotechnology

Beta	1.32
Market Cap	15M
PE Ratio	None
Target Price	18.5
Dividend Yield	None

ABOUT

BiomX Inc

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. The company was founded in 2015 and is headquartered in Ness Ziona, Israel.

PHGE · BiomX Inc

-

BiomX Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest BiomX Inc using a moving average strategy